Europe Stem Cell Therapy Market, By Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors) Industry Trends and Forecast to 2029
Market Analysis and Size
Chronic diseases-including cancer, musculoskeletal disorders and neurology disorders, chronic injuries, cardiovascular and gastrointestinal-can lead to hospitalization, long-term disability, reduced quality of life, and death.
The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung, and spinal cord injuries, and improve the state of autoimmune diseases, liver, and bone and cartilage diseases. Stems cells are a potent tool for the treatment of infections caused by inflammation, immune system failure, and, or tissue degeneration.
The drivers responsible for the growth of the Europe stem cell therapy market are the increased incidence of chronic diseases, rise in GMP-certification approvals for cell therapy production facilities, growing biotechnology sector and rise in clinical trials for stem-cell-based therapies. However, factors that are expected to restrain the market growth are the rise in the cost of stem cell-based research, and the risks faced while undergoing stem cell therapy, and the availability of alternatives.
The Europe stem cell therapy is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the Europe stem cell therapy market is expected to reach the value of USD 8.15 million and grow at a CAGR of 10.0% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Year |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors) |
|
Countries Covered |
意大利、比利时、捷克共和国、德国、英国、西班牙、匈牙利和波兰 |
|
涵盖的市场参与者 |
武田药品工业株式会社、Holostem Terapie Avanzate Srl、JCR Pharmaceuticals Co., Ltd、ANTEROGEN.CO., LTD、MEDIPOST、Orthofix Medical Inc.、BioRestorative Therapies, Inc.、STEMPEUTICS RESEARCH PVT LTD、Pluristem Inc. 等 |
市场定义
干细胞是人体的原始材料，所有其他具有特殊功能的细胞都是从干细胞中产生的。在体内或实验室的适当条件下，干细胞会分裂形成更多细胞，称为子细胞。子细胞成为具有更特定功能的新干细胞或特化细胞（分化），例如血细胞、脑细胞、心肌细胞或骨细胞。干细胞引起了研究科学家的极大兴趣。利用干细胞了解疾病的发展和发生方式、产生健康细胞来替代细胞以及测试新药的安全性和有效性是使用干细胞疗法的科学原因。
干细胞疗法利用干细胞或衍生物促进功能失调或受伤的组织修复反应。这是器官移植的下一个篇章，使用细胞代替供应有限的供体器官。成体干细胞，如脂肪组织衍生的间充质干细胞、骨髓衍生的间充质干细胞以及胎盘或脐带干细胞，在大多数组织中数量较少。胚胎干细胞来源于三到五天大的胚胎。新出现的迹象表明，成体干细胞可能能够产生各种类型的细胞。
欧洲干细胞治疗市场动态
驱动程序
- 慢性病患病率和发病率上升
慢性病是全球常见的健康问题。在欧洲，三分之一的成年人患有慢性病。慢性病影响了许多公民的健康和生活质量。慢性病（包括癌症、肌肉骨骼疾病和神经系统疾病、慢性损伤、心血管和胃肠道疾病）可能导致住院、长期残疾、生活质量下降甚至死亡。
间充质干细胞可渗透并整合至多种器官，修复心血管、肺脏和脊髓损伤，改善自身免疫性疾病、肝脏、骨和软骨疾病。干细胞是治疗由炎症、免疫系统衰竭和/或组织退化引起的疾病的有力工具。
例如，
- 2021 年，根据世界卫生组织 (WHO) 的数据，全球约有 17 亿人患有肌肉骨骼疾病。腰痛是肌肉骨骼疾病的高负担。
- 干细胞研究的研发和资金可用性增加
干细胞研究由美国国立卫生研究院 (NIH) 预算资助。私营部门也资助干细胞研究，但这种投资通常发生在后期，即测试和开发阶段，然后是初始基础研究。由于干细胞疗法是一个如此新的领域，必须有一个公正的政府机构对其进行监督。FDA 谨慎而周到，但他们一直在为资金而苦苦挣扎，进行长期投资，将付款与未来的潜在受益者联系起来。
例如，
- 2021年12月，在英国，MRC和生物技术委员会以及BBSRC资助英国干细胞库开展研究项目，建立符合伦理道德、质量可控、有保证的人类胚胎、胎儿和成体干细胞系库。
- 细胞治疗生产设施 GMP 认证批准数量增加
GMP 确保产品始终按照适合其预期用途的先进质量标准进行生产和控制。因此，GMP 原则对于向消费者和患者提供质量稳定、安全性高的产品做出了巨大贡献。
获得 GMP 认证将有助于预防错误。获得的认证允许制造商在相同、可重复、无菌的环境中生产细胞系。因此，GMP 认证可能会促进欧洲干细胞治疗市场的增长。
机会
- 医疗支出的增加
此外，研发活动的增加以及政府和私人组织投资的增加将为市场增长率带来新的机遇。
例如，
- 根据欧盟统计局的数据，2020 年欧盟卫生支出为 13.096 亿美元
- 市场参与者的战略举措
由于慢性病的及时治疗，欧洲对干细胞治疗的需求增加。这些有利因素增加了对药物的需求，为了满足市场需求，大大小小的市场参与者都在采用各种策略。
主要参与者还试图制定具体的策略，例如产品发布、收购、批准、扩张和合作，以确保业务顺利进行，避免风险，并增加市场销售的长期增长。
市场参与者的这些战略举措，包括收购、会议和重点细分产品发布，正在帮助公司发展并改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措提供了一个帮助他们推动市场增长的机会。
限制/挑战
- 干细胞治疗研究成本的上升
干细胞疗法是一种正在发展中的新型治疗选择，可用于治疗多种疾病。有时，治疗费用是多种疾病的一大顾虑。干细胞治疗程序。干细胞领域仍然高度专业化，尚未被主流和保险公司所采用。基于干细胞疗法的研究治疗费用不在医疗保险范围内。这些费用被转嫁给患者。因此，目前的高成本预计将呈现下降趋势。
例如，
- 2021 年，Podari Zhizn 的英国姊妹慈善机构 Gift of Life 的数据显示，肌肉骨骼疾病的干细胞治疗费用为 4861.44 美元至 5401.60 美元
- 接受干细胞治疗时面临的风险
干细胞治疗师和研究科学家在开发干细胞治疗模型时观察到了特定的风险。使用干细胞疗法面临的主要挑战是最佳细胞来源。干细胞疗法在发达国家已经成熟并迅速发展；然而，某些风险阻碍了这种疗法在发展中国家的发展。这些标准限制了干细胞疗法的使用。因此，接受干细胞治疗的患者会面临某些风险。
例如，
- 干细胞治疗面临的风险包括基因不稳定、肿瘤形成、不适当的干细胞形成、移植干细胞的免疫排斥、神经外科手术期间出血以及术后感染
- 干细胞移植后面临的风险是移植后干细胞分布和定位不当。多能干细胞可形成畸胎瘤（肿瘤）
- 严格的规定
与旧有的监管指南相比，干细胞疗法的监管指南更为严格。制造商必须在获得批准之前对产品进行特定的更改，这预计会导致延误。公司必须仔细审查产品规格和认证，然后才能根据食品药品管理局 (FDA) 和欧盟 (EU) 对其产品进行分类。每个国家都有监管机构负责执行药品开发、许可、注册、制造、营销和药品标签的规则和法规。
FDA 的生物制品评估与研究中心 (CBER) 负责监管用于移植的人体组织、细胞和组织产品，包括造血干细胞。
例如，
- 在英国，药品和保健产品管理局 (MHRA) 负责监管和提供干细胞治疗的指导方针；当干细胞治疗被视为药品 (MP) 时，出于质量和安全 (Q and S) 的考虑，测试法规
欧洲干细胞治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关欧洲干细胞治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报；我们的团队将帮助您做出明智的市场决策，以实现市场增长。
患者流行病学分析
欧洲干细胞治疗市场还为您提供详细的市场分析，包括患者分析、预后和治疗。患病率、发病率、死亡率和依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更全面的多元统计模型，用于预测增长期间的市场。
COVID-19 对欧洲干细胞治疗市场的影响
在疫情期间，干细胞疗法对降低 COVID-19 患者的死亡率和发病率有显著作用。需要进一步的大规模研究来证实这些结果。应制定针对 COVID-19 感染的干细胞治疗方案，以实现最佳的临床结果。在 COVID-19 期间进行了临床试验。
近期发展
- 2020 年 9 月，武田药品工业株式会社获得日本厚生劳动省的产品批准，生产和销售 Alofisel (darvadstrocel) 和脂肪来源的间充质干细胞，用于治疗无活动性或轻度活动性腔内克罗恩病 (CD) 患者的复杂肛周瘘。获得的批准将导致上市后批准和产品上市。这有望促进市场增长。
欧洲干细胞治疗市场范围
欧洲干细胞治疗市场根据产品类型、类型、应用、最终用户和分销渠道分为五个部分。这些部分之间的增长将帮助您分析行业中增长微弱的部分，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
产品类型
- 骨髓间充质干细胞
- 胎盘或脐带干细胞
- 脂肪组织来源的间充质干细胞
- 其他的
根据产品类型，欧洲干细胞治疗市场分为骨髓间充质干细胞、胎盘或脐带干细胞、脂肪组织间充质干细胞等。
类型
- 同种异体干细胞治疗
- 自体干细胞治疗
根据类型，欧洲干细胞治疗市场分为同种异体干细胞治疗和自体干细胞治疗。
应用
- 肌肉骨骼疾病
- 伤口和损伤
- 急性移植物抗宿主病 (AGVHD)
- 手术
- 胃肠道疾病
- 心血管疾病
- 其他的
根据应用，欧洲干细胞治疗市场细分为肌肉骨骼疾病、伤口和损伤、急性移植物抗宿主病 (AGVHD)、手术、胃肠道疾病、心血管疾病等。
最终用户
- 医院和外科中心
- 治疗公司
- 服务公司
- 其他的
根据最终用户，欧洲干细胞治疗市场分为医院和外科中心、治疗公司、服务公司和其他。
分销渠道
- 直接招标
- 第三方分销商
根据分销渠道，欧洲干细胞治疗市场分为直接招标和第三方分销商。
欧洲干细胞治疗市场区域分析/见解
对欧洲干细胞治疗市场进行了分析，并按地区、产品类型、类型、应用、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。
欧洲干细胞治疗市场报告涵盖的一些国家包括意大利、比利时、捷克共和国、德国、英国、西班牙、匈牙利和波兰。由于干细胞研究临床试验的批准和人类干细胞领域的发展增加，意大利预计将主导市场。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些因素和法规变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和欧洲干细胞治疗市场份额分析
The Europe stem cell therapy market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Europe stem cell therapy market.
Some of the major players operating in the Europe stem cell therapy market are Takeda Pharmaceutical Company Limited, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Orthofix Medical Inc., BioRestorative Therapies, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe versus Regional, and Vendor Share Analysis. To know more about the research methodology, drop an inquiry to speak to our industry experts.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE STEM CELL THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR THE EUROPE STEM CELL THERAPY MARKET
7 EUROPE STEM CELL THERAPY MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH
8.1.3 GROWING BIOTECHNOLOGY SECTOR
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES
8.2 RESTRAINTS
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH
8.2.4 AVAILABILITY OF ALTERNATIVES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY
8.4.2 STRINGENT REGULATIONS
9 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS
9.3 PLACENTAL/UMBILICAL STEM CELL
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS
9.5 OTHERS
10 EUROPE STEM CELL THERAPY MARKET, BY TYPE
10.1 OVERVIEW
10.2 ALLOGENEIC STEM CELL THERAPY
10.2.1 MUSCULOSKELETAL DISORDERS
10.2.2 WOUNDS AND INJURIES
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
10.2.4 SURGERIES
10.2.5 GASTROINTESTINAL DISEASES
10.2.6 OTHER APPLICATION
10.3 AUTOLOGOUS STEM CELL THERAPY
10.3.1 CARDIOVASCULAR DISEASES
10.3.2 GASTROINTESTINAL DISEASES
10.3.3 OTHER APPLICATION
11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MUSCULOSKELETAL DISORDERS
11.3 WOUNDS AND INJURIES
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
11.5 SURGERIES
11.6 GASTROINTESTINAL DISEASES
11.7 CARDIOVASCULAR DISEASES
11.8 OTHER APPLICATION
12 EUROPE STEM CELL THERAPY MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND SURGICAL CENTERS
12.3 THERAPEUTIC COMPANIES
12.4 SERVICES COMPANIES
12.5 OTHERS
13 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 THIRD PARTY DISTRIBUTORS
14 EUROPE STEM CELL THERAPY MARKET, BY REGION
14.1 EUROPE
14.1.1 ITALY
14.1.2 BELGIUM
14.1.3 CZECH REPUBLIC
14.1.4 GERMANY
14.1.5 U.K.
14.1.6 SPAIN
14.1.7 HUNGARY
14.1.8 POLAND
15 EUROPE STEM CELL THERAPY MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021)
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 ORTHOFIX MEDICAL INC. (2021)
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 MEDIPOST (2021)
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 CORESTEM, INC. (2021)
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PHARMICELL CO., LTD. (2021)
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ANTEROGEN.CO., LTD (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 ATHERSYS, INC.(2021)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 BRAINSTORM CELL LIMITED (2021)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENTS
17.11 BIORESTORATIVE THERAPIES, INC. (2021)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 INTERNATIONAL STEMCELL CORPORATION (2021)
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 MESOBLAST LTD (2021)
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 PLURISTEM INC.(2021)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 STEMPEUTICS RESEARCH PVT LTD
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 U.S. STEM CELL, INC. (2021)
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 20 EUROPE HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 25 EUROPE DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 28 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 33 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 ITALY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 ITALY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 ITALY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 ITALY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 39 ITALY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 40 ITALY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 ITALY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 BELGIUM STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 43 BELGIUM STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 BELGIUM ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 BELGIUM AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 BELGIUM STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 47 BELGIUM STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 BELGIUM STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 49 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 CZECH REPUBLIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 52 CZECH REPUBLIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 54 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 GERMANY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 GERMANY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 GERMANY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 61 GERMANY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 GERMANY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 63 U.K. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.K. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.K. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 U.K. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 U.K. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 68 U.K. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 U.K. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 SPAIN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 71 SPAIN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SPAIN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 SPAIN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 SPAIN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 75 SPAIN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 SPAIN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 HUNGARY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 78 HUNGARY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 HUNGARY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 80 HUNGARY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 HUNGARY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 82 HUNGARY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 HUNGARY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 POLAND STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 85 POLAND STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 POLAND ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 POLAND AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 POLAND STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 89 POLAND STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 POLAND STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE STEM CELL THERAPY MARKET : SEGMENTATION
FIGURE 2 EUROPE STEM CELL THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE STEM CELL THERAPY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE STEM CELL THERAPY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE STEM CELL THERAPY MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE STEM CELL THERAPY MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE EUROPE STEM CELL THERAPY MARKET FROM 2022 TO 2029
FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE STEM CELL THERAPY MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE STEM CELL THERAPY MARKET
FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022
FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020
FIGURE 17 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021
FIGURE 18 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 19 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 20 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2021
FIGURE 22 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 23 EUROPE STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 EUROPE STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2021
FIGURE 26 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 27 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 28 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2021
FIGURE 30 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 EUROPE STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 32 EUROPE STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 34 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 35 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 36 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 EUROPE STEM CELL THERAPY MARKET: SNAPSHOT (2021)
FIGURE 38 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021)
FIGURE 39 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022 & 2029)
FIGURE 42 EUROPE STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
